We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Innovations Increase Sensitivity of CTC Detection

By LabMedica International staff writers
Posted on 28 Mar 2018
Innovations in the methodology used to collect circulating tumor cells (CTCs) from blood specimens will allow reliable monitoring of CTC changes during and after treatment.

The detection of CTCs may have important prognostic and therapeutic implications, but because their numbers can be very small, these cells are not easily detected. More...
It has been estimated that among the cells that have detached from a primary tumor, only 0.01% can form metastases. Circulating tumor cells are found in frequencies on the order of one to 10 CTCs per milliliter of whole blood in patients with metastatic disease. For comparison, one milliliter of blood contains a few million white blood cells and a billion red blood cells. This low frequency, associated to difficulty of identifying cancerous cells, means that a key component of understanding CTCs biological properties require technologies and approaches capable of isolating one CTC per milliliter of blood, either by enrichment, or with enrichment-free assays that identify all CTC subtypes in sufficiently high definition to satisfy diagnostic pathology image-quantity requirements in patients with a variety of cancer types.

Towards this end, investigators at the University of Wisconsin (Madison, USA) examined the effects of multivalent binding and biomimetic cell rolling on the sensitivity and specificity of CTC capture. They also investigated the clinical significance of CTCs and their kinetic profiles in cancer patients undergoing radiotherapy (RT) treatment.

For the study peripheral blood was collected prospectively at up to five time points from 24 patients with head-and-neck, prostate, rectal, or cervical cancer who were undergoing radiation therapy (RT), with or without chemotherapy.

CTC capture was accomplished using the Capio Biosciences (Madison, WI, USA) CapioCyte nanotechnology-based assay system functionalized with anti-EpCAM (Epithelial cell adhesion molecule), anti-HER-2 (human epidermal growth factor receptor 2), and anti-EGFR (Epidermal growth factor receptor).

The CapioCyte platform utilizes proprietary chips that are inserted into a specially designed flow chamber. Samples are then passed through this flow chamber at a precisely controlled rate. The surface of the chip is specially treated to induce biomimetic cell rolling to enable cell capture utilizing antibodies bound to dendrimers. Cell rolling mimics the physiological interaction of CTCs and blood vessel walls, slowing movement and recruiting and enriching cells within the flow chamber. Once captured, CTCs can either be recovered for post capture analysis such as RNA-Seq, or they can be automatically stained for subsequent fluorescence image capture.

Results published in the March 15, 2018, online edition of the journal Clinical Cancer Research revealed that the CapioCyte system was able to detect CTCs in all 24 cancer patients. Multivalent binding via poly(amidoamine) dendrimers further improved capture sensitivity. The cell rolling effect improved CTC capture specificity by up to 38%. CTCs declined throughout RT in patients with complete clinical and/or radiographic response, in contrast to an elevation in CTCs at mid or post-RT in the two patients with known pathologic residual disease.

"The absolute numbers of CTCs do not represent too much because there is too much variation individually, but the more important thing we found was the trend - how the CTC numbers change over time upon treatment. So, for example, we have shown that the CTCs go down when the patients are responding really well to the radiotherapy," said senior author Dr. Seungpyo Hong, professor of pharmacy at the University of Wisconsin. "What makes us excited in particular is we can see the direct impact. As a researcher, if you develop a new technology and it can directly help people, that is going to be the most rewarding experience – it is really exciting."

Related Links:
University of Wisconsin
Capio Biosciences


Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.